Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Cerus Corporation (NASDAQ: CERS), a biomedical products company focused on blood transfusion safety and pathogen-protected blood components. These filings offer detailed information on the company’s financial performance, business risks, and corporate governance.
Investors can review current reports on Form 8-K, which Cerus uses to furnish press releases announcing quarterly financial results, such as second and third quarter 2025 earnings. These 8-K filings summarize product revenue from INTERCEPT platelet, plasma, and INTERCEPT Fibrinogen Complex (IFC) sales, government contract revenue related to INTERCEPT RBC and other development programs, and updates to annual product revenue guidance.
Cerus’ periodic reports on Form 10-K and Form 10-Q, referenced in company press releases, include sections such as “Risk Factors” that discuss uncertainties related to commercialization of the INTERCEPT Blood System, regulatory approvals for the INTERCEPT RBC system, development of technologies like INT200 and lyophilized IFC, supply chain considerations, and macroeconomic and geopolitical risks.
Through this page, users can also monitor disclosures about board and leadership changes, such as those reported in Form 8-K filings covering director retirements and appointments of new board leadership roles. These documents provide context on the company’s governance structure.
Stock Titan enhances these filings with AI-powered tools that summarize lengthy documents, highlight key items such as revenue trends, development program updates, and risk factor changes, and help readers navigate complex regulatory language. Users can quickly locate information on topics like product revenue composition, government contract funding, and the status of clinical and regulatory programs related to Cerus’ INTERCEPT technologies.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported both a stock grant and a tax-related sale of common shares. On March 5, 2026, he acquired 80,320 shares of common stock as a grant or award, increasing his direct holdings to 1,946,968 shares.
On March 6, 2026, he executed an open-market Rule 10b5-1 sale of 34,094 shares at a weighted average price of $2.0055 per share to cover statutory tax withholding obligations and related brokerage fees, a non-discretionary transaction that left him with 1,912,874 directly held shares.
CERUS CORP President and CEO William Mariner Greenman reported offsetting stock transactions. On March 5, 2026, he acquired 193,270 shares of common stock as a grant at $0.0000 per share. On March 6, 2026, he sold 78,187 shares at a weighted average price of $2.0055 per share pursuant to a Rule 10b5-1 instruction to cover statutory tax withholding and related brokerage fees. Following these transactions, he held 5,446,250 shares directly.
CERS insider sale filings reported by Richard J. Benjamin. The filing shows sales of 24,235 common shares on 03/06/2026 for $48,603.19 and 61,233 common shares on 03/05/2026 for $126,299.19. A broker-dealer listed is Morgan Stanley Smith Barney LLC with a reference date of 03/09/2026. The record also references 40,426 common shares tied to restricted stock dated 03/06/2025.
Morgan Stanley Smith Barney LLC notified a proposed sale of common stock for issuer-restricted shares related to CERS. The notice lists proposed sale activity tied to restricted stock grants dated 03/12/2023 (43,092 shares) and 03/12/2024 (12,133 shares), and references an aggregate number 192,171,776.
Morgan Stanley Smith Barney LLC submitted a Form 144 notice reporting the proposed sale of restricted common stock of the issuer CERS (NASDAQ). The filing lists 52,385 restricted shares dated 03/12/2024 and 8,848 restricted shares dated 03/12/2022.
Cerus Corp’s chief medical officer, Benjamin Richard J, reported an equity grant on Form 4. On March 2, 2026, he acquired 264,000 shares of common stock in the form of restricted stock units at a stated price of $0.00 per share. Following this award, he directly holds 949,775 common shares. Each RSU converts into one share and vests in two installments: 34% on March 12, 2027 and 66% on March 12, 2028, subject to his continuous service with Cerus through each vesting date.
Green Kevin Dennis reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corporation’s Chief Financial Officer Kevin Dennis Green reported an award of 300,000 restricted stock units, each representing one share of common stock. The grant was at no cash cost to him and increases his direct holdings to 1,187,262 shares, including prior employee stock purchase plan shares.
The RSUs vest in two stages: 34% on March 12, 2027 and 66% on March 12, 2028, conditioned on his continued service with the company through each vesting date.
Cerus Corp reported that President and CEO William Mariner Greenman received a grant of 1,200,000 restricted stock units (RSUs), each representing one share of common stock. The RSUs vest with 34% on March 12, 2027 and 66% on March 12, 2028, contingent on his continued service. Following this equity award and recent employee stock purchase plan acquisitions, his direct holdings total 5,331,167 shares of Cerus common stock.
Jayaraman Vivek K reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp Chief Operating Officer Vivek K. Jayaraman reported an award of 420,000 restricted stock units representing common shares on March 2, 2026, at a stated price of $0.00 per share. These RSUs vest in two annual installments, with 34% vesting on March 12, 2027, and 66% vesting on March 12, 2028, contingent on his continuous service with the company through each vesting date.
After this grant, his directly held common stock, including shares from the company’s employee stock purchase plan, totals 1,866,648 shares. This total includes 5,318 shares purchased on August 29, 2025, and 10,004 shares purchased on February 27, 2026, under the employee stock purchase plan.
Jensen Chrystal reported acquisition or exercise transactions in this Form 4 filing.
Cerus Corp reported that Chief Legal Officer Chrystal Jensen received a grant of 300,000 shares of common stock in the form of restricted stock units. These RSUs vest in two steps: 34% on March 12, 2027 and 66% on March 12, 2028, contingent on continued service. After this award, Jensen directly holds 1,028,294 shares.